Weekly Recap | BEONE MEDICINES -0.37%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.The Week
BEONE MEDICINES (6160.HK) slipped 0.37% this week to close at HK$216.4, outperforming the Hang Seng Index’s 2.13% decline by about 1.76 percentage points. The stock opened Monday at HK$219, hit a weekly high of HK$221.4, then pulled back to a low of HK$214 on Wednesday before steadying on Thursday. The weekly range was 3.38%, with trading activity noticeably lighter than the recent median. No major catalyst emerged.
Analyst Ratings
Among the 18 analysts covering the stock, 14 rate it buy, 3 rate it overweight, and 1 rates it hold. The consensus rating is strong buy. The consensus target price is HK$263.542, about 21.8% above the latest close, with targets ranging from HK$226.039 to HK$321.760 — a wide spread. The stock ranks 4th among 52 names in the biotech industry by analyst rating.
The Week Ahead
Watch whether the pharma sector can maintain its relative strength against a softer broader market. This week’s brief outperformance came alongside falling volumes, suggesting limited conviction; the next move likely depends on fresh industry news or company updates.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.